Solventum Corporation (SOLV)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Solventum Corporation keeps $4 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Solventum beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 5, as revenue and adjusted EPS both came in above consensus. Revenue rose 2% to about $2.2 billion, topping the about $2.2 billion estimate by about 3%, while adjusted EPS of $2.55 beat the $1.90 forecast by about 34% and improved from $1.69 a year earlier. Net income rose 2% to roughly $92.0 million from $90.0 million a year ago, with gross margin near 58% and operating margin around 8% on operating income of about $181 million. Operating cash flow came in at $38.0 million, and the company repurchased about $355.0 million of stock.
About Solventum Corporation
Solventum Corporation is a healthcare company listed on the NYSE under SOLV that sells medical devices, dental and orthodontic products, clinical and revenue-cycle software, and filtration technologies across care settings and healthcare workflows. Across these businesses, Solventum generated $8.3 billion in revenue in FY2025.
Today's Snapshot
The session opened with SOLV 1% lower at 89.12, while its sector was flat.
Trading Volume
Below 10d avg (759.4K)
98K
vs S&P 500 Today
Underperforming Market
-0.85%
Updated: September 10, 2026 at 15:07 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$78.82 - $90.41Buy
- RSI (14)52.29Neutral
- Stochastic %K (14, 3, 3)34.67Neutral
- MACD Level (12, 26)1.62Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.